retatrutide and addiction GLP-1 medications get at the heart of addiction: study – WashU Medicine Is a new weight-loss drug

GIP Receptor Activation Glucose-dependent insulinotropic polypeptide receptor activation adds metabolic benefits beyond appetite control

showed that liraglutide 1.8 mg/day for 6 months, along with a mean weight loss of 5.2 kg, was effective in significantly reduce fasting glucose and HbA1c, while HOMA-IR and other insulin resistance parameters remained unchanged [64]

Inmode Aesthetics: C

Nagae K, Uchi H, Morino-Koga S, et al

Think of it as a bridge between active weight loss and long-term maintenance, especially during the critical months right after stopping GLP-1 therapy

Obesity prevalence has doubled since 1990, with one in eight individuals being obese worldwide